Tumour necrosis factor-betaAlternative Names: Lymphotoxin
Latest Information Update: 14 Mar 2008
At a glance
- Originator Genentech
- Developer Kanegafuchi Chemicals
- Class Antihyperglycaemics; Antineoplastics; Antivirals; Cytokines; Tumour necrosis factors
- Mechanism of Action Immunomodulators; Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Type 1 diabetes mellitus